Intestinal Research

Case Report

IBD

Hyperbaric oxygen therapy for pyoderma gangrenosum associated with ulcerative colitis: Hyun Il Seo, Hyun-Ju Lee, Koon Hee Han; Intest Res 2018;16(1):155-157. Published online January 18, 2018; DOI: https://doi.org/10.5217/ir.2018.16.1.155

Pyoderma gangrenosum (PG), an ulcerating skin condition, is rare in patients with ulcerative colitis (UC). We report a case of successful treatment of PG in a patient with UC using hyperbaric oxygen therapy (HBOT). The patient had UC that was in remission following treatment with mesalazine and azathioprine therapy. After visiting an orthopedic clinic, the patient opted for treatment with antibiotics and daily dressing of the ulcerative skin lesions, while azathioprine was discontinued. However, the lesions did not improve. Two months later, the patient visited a dermatologist who diagnosed the lesions as PG, and he was admitted to our unit. Surgical debridement and HBOT were performed by a plastic surgeon in the emergency department. After 3 months of HBOT and topical treatment, the patient's PG completely resolved. His UC was still in remission with mesalazine alone. HBOT may be an effective and safe alternative treatment for PG associated with UC, particularly in patients in whom anti-tumor necrosis factor agents are unnecessary.

Citations

Citations to this article as recorded by

The new insights of hyperbaric oxygen therapy: focus on inflammatory bowel disease
Leilei Chen, Yan Wang, Huihui Zhou, Yi Liang, Fengqin Zhu, Guangxi Zhou
Precision Clinical Medicine.2024;[Epub] CrossRef
Emerging Indications for Hyperbaric Oxygen Treatment: Registry Cohort Study
Hideaki L Tanaka, Judy R Rees, Ziyin Zhang, Judy A Ptak, Pamela M Hannigan, Elaine M Silverman, Janet L Peacock, Jay C Buckey
Interactive Journal of Medical Research.2024; 13: e53821. CrossRef
EFICÁCIA DA OXIGENOTERAPIA HIPERBÁRICA NO TRATAMENTO DE PIODERMA GANGRENOSO
Ana Júllia Almeida Ferreira, Natally Macedo Torrente, Pedro Paulo Custódio Martinez Sacchi, Poliana Pezzotto
RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218.2024; 5(9): e595755. CrossRef
Treatment of Pyoderma Gangrenosum With Mycophenolate and Hyperbaric Oxygen Therapy: A Case Report and Literature Review
Subo Dey, Nirali Sanghavi, Amy Wasserman, Kausik Kar
Cureus.2023;[Epub] CrossRef
Efficacy and safety evaluation of hyperbaric oxygen therapy for patients with ulcerative colitis
Wei Wang, Ying He, Dou Wen, Shangshang Jiang, Xiaodong Zhao
Medicine.2021; 100(1): e23966. CrossRef
Adjunctive Hyperbaric Oxygen Therapy in Refractory Crohn’s Disease: An Observational Study
Marley R. Feitosa, Rogério S. Parra, Vanessa F. Machado, Gustavo N. Vilar, Jussara C. Aquino, José J. R. Rocha, Paulo G. Kotze, Omar Féres, Chiara Ricci
Gastroenterology Research and Practice.2021; 2021: 1. CrossRef
The role of hyperbaric oxygen therapy in inflammatory bowel disease
Xin Wu, Tian-Yu Liang, Zhong Wang, Gang Chen
Medical Gas Research.2021; 11(2): 66. CrossRef
Giant pyoderma gangrenosum in a patient with ulcerative colitis
Ruixian Niu, Jiangtao Zheng, Dongmei Ding, Weian Kuang, Fengyan Lu, Xunguo Yin
Medicine.2020; 99(6): e18795. CrossRef
Development of an International, Multicenter, Hyperbaric Oxygen Treatment Registry and Research Consortium: Protocol for Outcome Data Collection and Analysis
Nicole P Harlan, Judy A Ptak, Judy R Rees, Devin R Cowan, Abigail M Fellows, Judith A Kertis, Pamela M Hannigan, Janet L Peacock, Jay C Buckey
JMIR Research Protocols.2020; 9(8): e18857. CrossRef
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy
Giorgia Guaitoli, Federico Piacentini, Claudia Omarini, Alessia Andreotti, Enza Palma, Simona Papi, Chiara De Pietri, Andrea Conti, Stefano Cascinu, Giovanni Tazzioli
Breast Cancer.2019; 26(4): 520. CrossRef
Atypical wounds. Best clinical practice and challenges
Kirsi Isoherranen, Julie Jordan O'Brien, Judith Barker, Joachim Dissemond, Jürg Hafner, Gregor B. E. Jemec, Jivko Kamarachev, Severin Läuchli, Elena Conde Montero, Stephan Nobbe, Cord Sunderkötter, Mar Llamas Velasco
Journal of Wound Care.2019; 28(Sup6): S1. CrossRef
Pyoderma Gangrenosum: What Do We Know Now?
Fatima McKenzie, Megan Arthur, Alex G. Ortega-Loayza
Current Dermatology Reports.2018; 7(3): 147. CrossRef
Pyoderma gangrenosum – an interdisciplinary approach to the disease
Aleksandra Kapuśniak, Aleksandra Czachor, Grażyna Wąsik
Medical Science Pulse.2018; 12(4): 61. CrossRef

11,125 View
71 Download
12 Web of Science
13 Crossref

Images of the Issue

Two hyperemic polypoid lesions in the colon: Hyun Il Seo; Intest Res 2016;14(4):379-380. Published online October 17, 2016; DOI: https://doi.org/10.5217/ir.2016.14.4.379

PDF PubReader

12,906 View
46 Download
3 Web of Science

Original Article

Comparison of the efficacy of disinfectants in automated endoscope reprocessors for colonoscopes: tertiary amine compound (Sencron2®) versus ortho-phthalaldehyde (Cidex®OPA): Hyun Il Seo, Dae Sung Lee, Eun Mi Yoon, Min-Jung Kwon, Hyosoon Park, Yoon Suk Jung, Jung Ho Park, Chong Il Sohn, Dong Il Park; Intest Res 2016;14(2):178-182. Published online April 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.2.178

Abstract PDF PubReader ePub

Background/Aims

To prevent the transmission of pathogens by endoscopes, following established reprocessing guidelines is critical. An ideal reprocessing step is simple, fast, and inexpensive. Here, we evaluated and compared the efficacy and safety of two disinfectants, a tertiary amine compound (TAC) and ortho-phthalaldehyde (OPA).

Methods

A total of 100 colonoscopes were randomly reprocessed using two same automated endoscope reprocessors, according to disinfectant. The exposure time was 10 minutes for 0.55% OPA (Cidex® OPA, Johnson & Johnson) and 5 minutes for 4% TAC (Sencron2®, Bab Gencel Pharma & Chemical Ind. Co.). Three culture samples were obtained from each colonoscope after reprocessing.

Results

A total of nine samples were positive among the 300 culture samples. The positive culture rate was not statistically different between the two groups (4% for OPA and 2% for TAC, P=0.501). There were no incidents related to safety during the study period.

Conclusions

TAC was non-inferior in terms of reprocessing efficacy to OPA and was safe to use. Therefore, TAC seems to be a good alternative disinfectant with a relatively short exposure time and is also less expensive than OPA.

Citations

Citations to this article as recorded by

What doesn’t kill biofilm, makes them stronger: critical methodological considerations for endoscope reprocessing
R. Kanaujia, A. Sharma, M. Biswal, V. Singh
Journal of Hospital Infection.2025; 156: 135. CrossRef
Synthesis, Characterization and Investigation of Antimicrobial Activity of Orthophtaldehyde Nanoflowers
Gülten CAN SEZGİN, Nilay ILDİZ
Middle Black Sea Journal of Health Science.2023; 9(2): 245. CrossRef
A Manufacturer and User Facility Device Experience Analysis of Upper Aerodigestive Endoscopy Contamination: Is Flexible Laryngoscopy Different?
Roy Jiang, David A. Kasle, Faisal Alzahrani, Nikita Kohli, Michael Z. Lerner
The Laryngoscope.2021; 131(3): 598. CrossRef
Electrochemical and Spectrometric Study of Reactivity of Orthophthalaldehyde with Hydroxylamine: Mechanistic Considerations
Joël Donkeng‐Dazie, Jiří Urban, Jiří Ludvík
ChemistrySelect.2021; 6(20): 4881. CrossRef
Reactivity of orthophthalaldehyde with aliphatic, alicyclic and aromatic primary diamines: Electrochemical study and mechanistic considerations
Joël Donkeng Dazie, Alan Liška, Jiří Urban, Jiří Ludvík
Journal of Electroanalytical Chemistry.2018; 821: 131. CrossRef
Efficacy of Peracetic Acid (EndoPA®) for Disinfection of Endoscopes
Ji Min Lee, Kang-Moon Lee, Dae Bum Kim, Se Eun Go, Sungwoo Ko, Yoongoo Kang, Solim Hong
The Korean Journal of Gastroenterology.2018; 71(6): 319. CrossRef
Planarity of substituted pyrrole and furan rings in (3R*, 1′S*, 3′R*)-3-(1′-tert-butylamino-1′H, 3′ H-benzo[c]furan-3′-yl)-2-tert-butyl-2,3-dihydro-1H-benzo[c]pyrrol-1-one
Joel Donkeng Dazie, Alan Liška, Jiří Ludvík, Jan Fábry, Michal Dušek, Václav Eigner
Zeitschrift für Kristallographie - Crystalline Materials.2017; 232(6): 441. CrossRef

10,133 View
57 Download
4 Web of Science
7 Crossref

Letters to the Editor

Radiation Exposure and Functional Gastrointestinal Disease: Hyun Il Seo; Intest Res 2014;12(4):335-336. Published online October 27, 2014; DOI: https://doi.org/10.5217/ir.2014.12.4.335

PDF PubReader ePub

5,021 View
56 Download

Original Articles

The Effect of Infliximab on Patients with Ulcerative Colitis in Korea: Hyun Il Seo, Dong Il Park, Tae Oh Kim, You Sun Kim, Suck-Ho Lee, Ji Won Kim, Jae Hak Kim, Jeong Eun Shin; Intest Res 2014;12(3):214-220. Published online July 25, 2014; DOI: https://doi.org/10.5217/ir.2014.12.3.214

Abstract PDF PubReader ePub

Background/Aims

Infliximab was introduced recently as a rescue therapy for ulcerative colitis (UC) patients refractory to conventional treatments such as therapy with 5-amiono salicylic acids (5-ASA), immune modulators, and corticosteroids. However, there is insufficient data about its efficacy and safety in Korea.

Methods

From 7 tertiary referral hospitals, 33 patients who were treated with infliximab for moderate to severe (Mayo score 6-12) UC refractory to conventional treatment were recruited to this study. Clinical remission was defined as a total Mayo score of 2 or lower and every subscore less than 2. Partial response was defined as a decrease of Mayo score at least 3 points from baseline.

Results

Twenty-three patients (69.7%) showed clinical remission and 29 patients (87.8%) showed partial response in the observation period. When the remission and non-remission groups were compared in univariate analysis, only a higher total Mayo score at base line (11.0±0.9 vs. 9.9±1.5; P=0.04) was related to remission. The remission maintenance rate decreased with time in the Kaplan-Meier analysis. Two patients experienced re-remission after the first remission followed by aggravation during infliximab treatment. Three patients stopped infliximab treatment owing to adverse events including rhabdomyolysis, pneumonia, and fever of unknown origin.

Conclusions

If there is no choice except surgery for UC patients refractory to conventional treatment, infliximab is an effective and relatively safe treatment option for these patients in Korea.

Citations

Citations to this article as recorded by

Real-world utility of platelet count, hemoglobin, and iron levels as predictors of clinical response to vedolizumab in patients with ulcerative colitis: a retrospective, single-center study in Poland
Aleksandra Sobolewska-Włodarczyk, Jakub Orliński, Żaneta Witas, Łukasz Woźniak, Zuzanna Łysoń, Anita Gąsiorowska
BMC Gastroenterology.2026;[Epub] CrossRef
Evolution of inflammatory bowel disease in Korea: a 60-year perspective on clinical and research development
Suk-Kyun Yang
Intestinal Research.2025; 23(3): 233. CrossRef
Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report
Samaneh Mohagheghi Darehranj, Sudabeh Alatab, Homayoon Vahedi, Anahita Sadeghi, Alireza Sima, Masoud Malekzadeh, Amir Anoshiravani, Hafez Fakheri, Nasser Ebrahimi Daryani, Abdolhamid Mousavi, Fariborz Mansour-Ghanaei, Mohammad Javad Zahedi, Reza Malekzade
Middle East Journal of Digestive Diseases.2019; 12(1): 12. CrossRef
Novel treatments for inflammatory bowel disease
Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
The Korean Journal of Internal Medicine.2018; 33(1): 20. CrossRef
Evolutionary Profile of Severe Acute Ulcerative Colitis in Chronic Inflammatory Bowel Diseases
Hakima Abid, Fatima Babakhouya, Ihssane Mellouki, Mounia El Yousfi, Noureddine Aqodad, Dafr Allah Benajah, Adil Ibrahimi, Mohamed El Abkari
Open Journal of Gastroenterology.2018; 08(03): 107. CrossRef
Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea
Hyungil Seo, Kiju Chang, Sun-Ho Lee, Eun-Mi Song, Gwang-Un Kim, Myeongsook Seo, Ho-Su Lee, Sung-Wook Hwang, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
Scandinavian Journal of Gastroenterology.2017; 52(8): 857. CrossRef
Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin
Kymberley Thorne, Laith Alrubaiy, Ashley Akbari, David G. Samuel, Sian Morrison-Rees, Stephen E. Roberts
European Journal of Gastroenterology & Hepatology.2016; 28(4): 369. CrossRef
Efficacy and safety of CT‐P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
Yoon Suk Jung, Dong Il Park, Young Ho Kim, Ji Hyun Lee, Pyoung Ju Seo, Jae Hee Cheon, Hyoun Woo Kang, Ji Won Kim
Journal of Gastroenterology and Hepatology.2015; 30(12): 1705. CrossRef
Inflammatory Bowel Disease Cohort Studies in Korea: Present and Future
Jung Won Lee, Jong Pil Im, Jae Hee Cheon, You Sun Kim, Joo Sung Kim, Dong Soo Han
Intestinal Research.2015; 13(3): 213. CrossRef
Circulating Ghrelin Levels and Obestatin/Ghrelin Ratio as a Marker of Activity in Ulcerative Colitis
Ja Young Jung, Ji Bong Jeong, Ji Won Kim, Su Hwan Kim, Seong-Joon Koh, Byeong Gwan Kim, Kook Lae Lee
Intestinal Research.2015; 13(1): 68. CrossRef
How to Write Bibliographies for Citing Domestic Academic Resources
Hyun Jung Yi
The Korean Journal of Gastroenterology.2015; 65(1): 70. CrossRef
Does the Cyclosporine Still Have a Potential Role in the Treatment of Acute Severe Steroid-Refractory Ulcerative Colitis?
Chang Soo Eun, Dong Soo Han
Gut and Liver.2015;[Epub] CrossRef
Current and Emerging Biologics for Ulcerative Colitis
Sung Chul Park, Yoon Tae Jeen
Gut and Liver.2015; 9(1): 18. CrossRef

7,832 View
46 Download
8 Web of Science
13 Crossref

A Clinical Analysis of Gastrointestinal Stromal Tumors in Small Intestine: Comparison of Bleeding and Non-bleeding Group: Sang Jin Lee, Jong Kyu Park, Hyun Il Seo, Koon Hee Han, Young Don Kim, Woo Jin Jeong, Gab Jin Cheon, Jae Seok Song; Intest Res 2013;11(2):113-119. Published online April 30, 2013; DOI: https://doi.org/10.5217/ir.2013.11.2.113

Abstract PDF

Background/Aims
Gastrointestinal stromal tumors (GIST) in the small intestine are rare and can cause bleeding. The study investigated the clinical characteristics of GIST in the small intestine and to determine the factors related to gastrointestinal bleeding. Methods: We retrospectively evaluated the clinical outcomes of 22 patients with small bowel GIST who were pathologically diagnosed at Gangneung Asan Hospital between March 1997 and August 2012. Results: The median age was 63.5 (38-82) years. Nine patients (40.9%) had gastrointestinal bleeding, five patients (22.7%) had abdominal pain, two patients (9%) had palpable mass. The site of tumor was the duodenum in nine cases (40.9%), jejunum in 7 cases (31.8%), and ileum in six cases (27.3%). Most patients underwent small bowel resection or wedge resection but three patients underwent pancreaticoduodenectomy. Tumor size ranged from 1.6 to 19 cm (median 6.5 cm). The median mitotic rate was 2 (0-50)/50 high power fields (HPF). The median mitotic rate was 2 (0-50)/50 HPF. Five patients (25%) showed recurrence. Gender, aspirin or warfarin use, size and mitotic index of tumor, hospital stay, recurrence and survival were not significantly different between bleeding and non-bleeding group. Bleeding group showed older age, proximal location in small intestine and mucosal ulceration significantly. Conclusions: Small bowel GISTs with bleeding were marked by older age, mucosal ulceration and location of proximal small bowel (duodenum and jejunum) rather than distal small bowel (ileum). (Intest Res 2013;11:113-119)

Citations

Citations to this article as recorded by

Prognostic Significance of Ki-67 Expression in Patients Undergoing Surgical Resection for Gastrointestinal Stromal Tumor
Seong Yeon Jeong, Won Wo Park, You Sun Kim, Young Il Park, Seung Hyup Kim, Won Jae Yoon, Jeong Seop Moon, Byung Mo Lee, Seong Woo Hong, Yun Kyung Kang
The Korean Journal of Gastroenterology.2014; 64(2): 87. CrossRef

3,140 View
17 Download
1 Crossref

The Effect of Transfection of RET9 and RET51 on Apoptosis in SW48 and RKO Colon Cancer Cells: Hyun Il Seo, Dong Il Park; Intest Res 2013;11(1):28-33. Published online January 31, 2013; DOI: https://doi.org/10.5217/ir.2013.11.1.28

Abstract PDF: Background/Aims
Dependent receptor can transmit both positive signal: proliferation, differentiation or migration; and negative signal: apoptosis. It depends on the presence of its ligand. This study was performed to determine the effects of transfection of dependent receptors in human colon cancer cell lines. Methods: Two dependent receptors (rearranged during transfection [RET]9 and RET51) were transfected into three human colon cancer cell lines: SW48, RKO and V400. Then, half of them were treated with glial cell line-derived neurotrophic factor (GDNF). Using ELISA and caspase assay, apoptosis was measured. Dose-response relation between GDNF and apoptosis was also analyzed. A pcDNA was used as an empty vector. Results: After transfection of RET51, apoptosis was increased in SW48 (70% with ELISA and 119% with caspase assay) and RKO (255% with ELISA and 106% with caspase assay) cell lines when compared with the pcDNA group. V400 cell line did not show increased apoptosis. Transfection of RET9 did not induce apoptosis in all of the three human colon cancer cell lines. Treatment with GDNF 12 hours after transfection of RET51 decreased apoptosis in SW48 (66% with ELISA and 60% with caspase assay) and RKO (39% with ELISA and 57% with caspase assay) when compared with the cell lines transfected with RET51 only. Apoptosis was down-regulated with increasing concentration of GDNF in RKO cell line. Conclusions: This study showed that the apoptosis of human colon cancer cell line can be controlled by manipulating the dependent receptors and its ligands. We present the possibility of therapeutic method using dependent receptor in colon cancer. (Intest Res 2013;11:28-33)

3,444 View
36 Download

First
Prev
Page of 1
Next
Last

Search